Posting of 2017 Annual Report & Notice of 2018 AGM

EKF Diagnostics Holdings plc
("EKF", the "Company")

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, confirms that the Annual Report and Accounts for the year ended 31 December 2017 (“2017 Annual Report”), the Notice of the Annual General Meeting and a Form of Proxy are now available on the Company's website:

Annual Report 2017

2018 AGM Proxy Form

The 2017 Annual Report was posted to shareholders today on April 13 2018.

The AGM is to be held on 8 May 2018 at 11am at the offices of Harwood Capital LLP, 6 Stratton Street, Mayfair, London W1J 8LD.

EKF Diagnostics Holdings plc Julian Baines, CEO Richard Evans, Finance Director and COO	00 44 29 2071 0570
N+1 Singer Alex Price / Shaun Dobson	00 44 20 7496 3000
Walbrook PR Limited Paul McManus Lianne Cawthorne	00 44 20 7933 8780 or ekf@walbrookpr.com 00 44 7980 541 893 00 44 7584 391 303

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

Trading update

Exercise of Options and Total Voting Rights

Dividend Timetable Amendment

Half-year Report

EKF Diagnostics announces its unaudited interim results for the six months ended 30 June 2020.

Notice of results

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its interim results for the six months ended 30 June 2020 on Monday 14 September 2020.